Published in Vaccine Weekly, October 22nd, 2003
Aventis Pasteur, the human vaccines business of Aventis, has agreed to develop a candidate vaccine using a similar approach to that of the currently licensed inactivated polio vaccine. The agreement was signed on September 26, 2003.
"This is important research that could have an impact on public health throughout the world. We hope to be able to advance development of a SARS vaccine by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly